Oxaliplatin: A review of its use in combination therapy for advanced metastatic colorectal cancer

Drugs

Volumn 63, Issue 19, 2003, Pages 2127-2156

  Simpson, Dene ^a   Dunn, Christopher ^a   Curran, Monique ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Colorectal cancer; Oxaliplatin; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

ANTIEMETIC AGENT; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TRANSFORMATION; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; REVIEW; SENSORY NEUROPATHY; STEADY STATE; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VISCERAL METASTASIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG INTERACTIONS; HUMANS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EMESIS; GLOMERULUS;

EID: 0141995824     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363190-00013     Document Type: Review

References (152)

1. Walsh L, Poston G. The potential to increase curative liver resection rates in metastatic colorectal cancer. Eur J Surg Oncol 2002; 28 (8): 812-4
2. Mulcahy MF, Benson III AB. Recent and ongoing clinical trials for treating colorectal cancer. Expert Opin Invest Drugs 2002; 11 (6): 871-80
3. Armand J-P, Boige V, Raymond E, et al. Oxaliplatin in colorectal cancer: an overview. Semin Oncol 2000 Oct; 27 (5 Suppl. 10): 96-104
4. Carrato A, Gallego J, Díaz-Rubio E. Oxaliplatin: results in colorectal carcinoma. Crit Rev Oncol Hematol 2002 Oct; 44 (1): 29-44
5. Pelley RJ. Oxaliplatin: a new agent for colorectal cancer. Curr Oncol Rep 2001 Mar; 3 (2): 147-55
6. O'Dwyer PJ, Johnson SW. Current status of oxaliplatin in colorectal cancer. Semin Oncol 2003 Jun; 30 (3 Suppl. 6): 78-87
7. Rothenberg ML. Efficacy of oxaliplatin in the treatment of colorectal cancer. Oncology (Huntingt) 2000 Dec; 14 (12 Suppl. 11): 9-14
8. Culy CR, Clemett D, Wiseman LR. Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000 Oct; 60 (4): 895-924
9. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem Pharmacol 1996; 52: 1855-65
10. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993 Dec; 53: 5970-6
11. Raymond E, Louvet C, Tournigand C, et al. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. Int J Oncol 2002 Aug; 21 (2): 361-7
12. Zeghari-Squalli N, Raymond E, Cvitkovic E, et al. Cellular pharmacology of the combination of the DNA topoisomerase 1 inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999 May; 5: 1189-96
13. Raymond E, Buquet-Fagot C, Djelloul S, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil an the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8: 876-85
14. Mathé G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or l-OHP, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatin. Biomed Pharmacother 1989; 43: 237-50
15. Fischel J-L, Etienne M-C, Formento P, et al. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 1998 Oct; 4: 2529-35
16. Faivre S, Raymond E, Woynarowski JM, et al. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44: 117-23
17. Tashiro T, Kawada Y, Sakurai Y, et al. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane) platinum (II): new experimental data. Biomed Pharmacother 1989; 43: 251-60
18. Kornmann M, Fakler H, Butzer U, et al. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res 2000; 20 (5A): 3259-64
19. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001 Dec 1; 19 (23): 4298-304
20. Lenz H-J, Park DJ, Zhang W, et al. A multivariate analysis of genetic markers for clinical response to 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer [abstract no. 515]. Proc Am Soc Clin Oncol 2002 May 18; 21 (Pt 1): 129a
21. Sanofi-Synthelabo. Eloxatin (TM) (oxaliplatin for injection). Prescribing Information [online]. Available from URL: http://www.sanofi-synthelabous.com [Accessed 2003 Jul 7]
22. Delord J-P, Umlil A, Guimbaud R, et al. Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol 2003 Feb; 51 (2): 127-31
23. Kern W, Beckert B, Lang N, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol 2001 May; 12 (5): 599-603
24. Takimoto CH, Remick SC, Sharma S, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003 Jul 15; 21 (14): 2664-72
25. Joel S, Seymour F. Oxaliplatin (L-OHP) does NOT influence the pharmacokinetics of 5-fluorouracil (5-FU) [abstract no. 748]. 36th Proceedings of the American Society of Clinical Oncology; 2000 May 20-23; Denver (CO), 192a
26. Boisdron-Celle M, Craipeau MC, Brienza S, et al. Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemother Pharmacol 2002 Mar; 49 (3): 235-43
27. Cailleux PE, Delva R, Boisdron-Celle M, et al. Influence of oxaliplatin (LOHP) on 5-fluorouracil (5-FU) pharmacokinetics. Clinical consequences [abstract no. O56]. Ninth International Congress on Anti-Cancer Treatment 1999 Feb 2-5; Paris, 85
28. Papamichael D, Joel SP, Seymour MT, et al. Pharmacokinetic (PK) interaction between 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) [abstract no. 032]. Br J Cancer 1998; 78 Suppl. 2: 112
29. Fischel J-L, Formento P, Ciccolini J, et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer 2002 Apr 8; 86 (7): 1162-8
30. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000 Aug; 18 (16): 2938-47
31. Giachetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000 Jan; 18 (1): 136-47
32. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study [abstract no. 1009]. Proc Am Soc Clin Oncol 2003; 22: 252
33. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) [abstract no. 512 ]. Proc Am Soc Clin Oncol 2002 May 18; 21 (Pt 1): 129a
34. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003 Jun 1; 21 (11): 2059-69
35. Rougier P, Lepille D, Bennouna J, et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 2002 Oct; 13 (10): 1558-67
36. Carlson RH. FOLFOX4: clear benefit in colorectal cancer. Inpharma 2002 Jul; 1347: 13-4
37. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin or CPT-11 + 5FU/LV or oxaliplatin + CPT-11 in advanced colorectal cancer [oral presentation]. Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology 2003 May 31-Jun 3; Chicago (IL)
38. Rothenberg ML, Oza AM, Burger BG, et al. Phase III trial of bolus + infusional 5-FU/leucovorin vs oxaliplatin vs the combination in patients with recurrent metastatic colorectal cancer following irinotecan and bolus 5-FU/leucovorin [oral presentation]. Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology 2003 May 31-Jun 3; Chicago (IL)
39. Rothenberg ML, Oza AM, Burger B, et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan. 5-FU and leucovorin [abstract no. 1011]. Proc Am Soc Clin Oncol 2003; 22: 252
40. Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study [abstract no. 494]. Proc Am Soc Clin Oncol 2001 May 12; 20 (Pt 1): 124a
41. Cheeseman SL, Joel SP, Chester JD, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002 Aug 12; 87 (4): 393-9
42. Douillard J-Y, Sobrero A, Carnaghi C, et al. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann Oncol 2003; 14 Suppl. 2: ii7-ii12
43. Díaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients; a phase II multicentric study. Ann Oncol 1998; 9: 105-8
44. Bécouarn Y, Ychou M, Ducreux M, et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998 Aug; 16 (8): 2739-44
45. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-8
46. Lévi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29A (9): 1280-4
47. Messersmith W, Laheru D, Hidalgo M. Recent advances in the pharmacological treatment of colorectal cancer. Expert Opin. Invest. Drugs 2003; 12 (3): 423-34
48. Tebbutt NC, Cattell E, Midgley R, et al. Systemic treatment of colorectal cancer. Eur J Cancer 2002; 38: 1000-15
49. Comella P, Massidda B, Filippelli G, et al. Biweekly oxaliplatin (OXA) or irinotecan (IRI) with high dose folinic acid (FA) and 5-fluorouracil (FU) i.v. bolus in advanced colorectal carcinoma (ACC). Southern Italy Cooperative Oncology Group (SICOG 0103) randomized study [abstract no. 1123]. Proc Am Soc Clin Oncol 2003; 22: 280
50. Lévi F, Zidani R, Misset J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997 Sep; 350: 681-6
51. Casinello J, Escudero P, Salud A, et al. Activity of oxaliplatin (OXA) with weekly 5-fluorouracil (5-FU) bolus and low-dose folinic acid (FA) as first line treatment for advanced colorectal cancer (ACC) [abstract no. 284P]. Ann Oncol 2002; 13 Suppl. 5: 78-9
52. Hochster H, Chachoua A, Speyer J, et al. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol 2003 Jul 15; 21 (14): 2703-7
53. Guarneri D, Venturino A, Addamo G. Weekly oxaliplatin, bolus 5-FU and LV as first line treatment of metastatic colorectal cancer: preliminary results [abstract no. 315]. Ann Oncol 2002; 13 Suppl. 5: 87
54. Lichinitser M, Garin A, Gorbunova V. et al. Oxaliplatin (Oxa) combined with 4-hour 5-fluoro-uracil (5-FU) infusion and folinic acid (FA) every 2 weeks in patients with metastatic colorectal cancer (MCRC) [abstract no. 569]. Proc Am Soc Clin Oncol 2001 May 12; 20 (Pt 1): 143a
55. Ravaioli A, Marangolo M, Pasquini E, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol 2002 May 15; 20 (10): 2545-50
56. Carreca I, Agueli R, Mauceri M, et al. First-line therapy with bimonthly oxaliplatin and bolus 5-fluorouracil + folinic acid in advanced colorectal cancer [abstract no. 2360]. Proc Am Soc Clin Oncol 2002 May 18; 21 (Pt 2): 137b
57. Valcamonico F, Sava T, Padovani M, et al. Oxaliplatin first line chemotherapy in advanced colorectal cancer (ACC): a four years experience [abstract no. 1396]. Proc Am Soc Clin Oncol 2003 May; 22: 348
58. Mattioli R, Recchia P, Lippe C, et al. Bi-fractionated "folfox" as first line chemotherapy (CT) in elderly patients with metastatic colorectal cancer [abstract no. 1411]. 39th Annual Meeting American Society of Clinical Oncology 2003 May 31-Jun 3; Chicago (IL)
59. Fornari G, Mairone L, Tetti M, et al. Oxaliplatin + high dose 5FU + folinic acid (FOLFOX) as first line treatment in metastatic colorectal cancer [abstract no. A8]. Ann Oncol 2001; 12 Suppl.4: 4
60. Goldstein D, Michael M, Mitchell P, et al. Improving patient convenience: a modified schedule of FOLFOX (oxaliplatin combined with 5FU) with high activity and tolerability in untreated metastatic colorectal cancer (CRC) [abstract no. 578]. Proc Am Soc Clin Oncol 2001 May 12; 20 (Pt 1): 145a
61. Kouroussis C, Souglakos J, Kakolyris S, et al. Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology 2001; 61 (1): 36-41
62. André T, Figer A, Cervantes A, et al. FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized OPTIMOX study [abstract no. 1016]. 39th Annual Meeting American Society of Clinical Oncology 2003 May 31-Jun 3; Chicago (IL)
63. Luppi G, Zanelli F, Di Stasi A, et al. FOLFOX2 regimen in heavily pretreated patients with advanced colorectal cancer. Tumori 2002; 88 (4): 270-2
64. Alonso V, Herrero A, Zorrilla M, et al. Salvage treatment with oxaliplatin (LOHP)-based chemotherapy (CT) in heavily pretreated colorectal carcinoma (CRC). Proc Am Soc Clin Oncol May 2001; 20 (Pt 2): 110b
65. Patel J, Kemeny N, Gonen M, et al. A study of continuous infusion (CI) of fluorouracil (FU) and oxaliplatin (OXA) for previously treated colorectal cancer patients [abstract no. 568]. Proc Am Soc Clin Oncol 2001; 20 (Pt 1): 143a
66. Zucali PA, Carnaghi C, Rimassa L, et al. Biweekly oxaliplatin, and 5-fluorouracil/folinic acid as second-line treatment in patients with irinotecan refractory advanced colorectal cancer [abstract no. 2250]. Proc Am Soc Clin Oncol 2001 May 12; 20 (Pt 2): 125b
67. Schinzari G, Basso M, Quirino M, et al. Oxaliplatin combined with 5-fluorouracil and folinic acid in CPT 11 pretreated patients with advanced colorectal cancer [abstract no. A37]. Ann Oncol 2001; 12 Suppl. 4: 12
68. Muñoz Langa J, Bosch Roig C, Molins Palau C, et al. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer as a second or third line chemotherapy [abstract no. P141]. 11th International Congress on Anti-Cancer Treatment; 2001 Feb 6-9; Paris, 230-1
69. Moehler M, Hoffmann T, Hildner K, et al. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. Z Gastroenterol 2002 Dec; 40 (12): 957-64
70. Kouroussis C, Souglakos J, Mavroudis D, et al. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). Am J Clin Oncol 2002 Dec; 25 (6): 627-31
71. André T, Louvet C, Raymond E, et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9: 1251-3
72. Maindrault-Goebel F, Louvet C, André T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999; 35 (9): 1338-42
73. André T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999 Nov; 17 (11): 3560-8
74. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997 Feb; 33 (2): 214-9
75. Gerard B, Bleiberg H, Van Daele D, et al. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer. Anticancer Drugs 1998 Apr; 9 (4): 301-5
76. Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001 May; 37 (8): 1000-5
77. Hsieh RK, Chao T, Yang T, et al. Multicenter phase II study of oxaliplatin (Oxa), bolus 5-fluorouracil (5-FU) plus infusional high dose 5-FU/folinic acid (FA) combination in the treatment of advanced colorectal cancer resistant to 5-FU [abstract no. 2224]. Proc Am Soc Clin Oncol 2001 May 12; 20 (Pt 2): 118b
78. Lee JH, Lee JH, Kim TW, et al. Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer. J Korean Med Sci 2001 Feb; 16 (1): 69-74
79. Mosconi S, Cascinu S, Zaniboni A, et al. The value of oxaliplatin in combination with continuous infusion ±bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial. Tumori 2000; 86 (6): 465-9
80. Garufi C, Brienza S, Pugliese P, et al. Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. Anticancer Drugs 2000 Jul; 11 (6): 495-501
81. Recchia F, Rea S, Nuzzo A, et al. Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy. Oncol Rep 2003; 10 (1): 65-9
82. Salgado M, Vazquez S, Grande C, et al. A phase II study of biweekly oxaliplatin, fluorouracil 4 hour infusion and folinic acid, in pretreated metastatic colorectal cancer [abstract no. 2206]. Proc Am Soc Clin Oncol 2001 May 12; 20 (Pt 2): 114b
83. Ryan DP, Kulke MH, Fuchs CS, et al. Biweekly oxaliplatin in combination with a modified de Gramont 5-FU/leucovorin regimen in previously treated patients with advanced colorectal carcinoma [abstract no. 560]. Proc Am Soc Clin Oncol 2001; 20 (Pt 1): 141a
84. Maindrault-Goebel F, de Gramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000 Nov; 11 (11): 1477-83
85. Bismuth H, Adam R. Reduction of nonresectable liver metastases from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 1998; 25 (2 Suppl. 5): 40-6
86. Alberts SR, Donohue JH, Mahoney MR, et al. Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study [abstract no. 1053]. 39th Annual Meeting of the American Society of Clinical Oncology 2003 May 31-Jun 3; Chicago (IL)
87. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 2001; 8 (4): 347-53
88. Alberts SR. Intrahepatic therapy for resected hepatic metastases from colorectal carcinoma. Oncology (Huntingt) 2000 Dec; 14 (12 Suppl. 11): 48-51
89. Lévi F, Zidani R, Brienza S, et al. A multicenter evaluation of intensified, ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. Cancer 1999 Jun; 85 (12): 2532-40
90. Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224 (4): 509-22
91. Giachetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-9
92. Gaspar EM, Artigas V, Montserrat E, et al. Single centre study of L-OHP/5-FU/LV before liver surgery in patients with NOT optimally resectable colorectal cancer isolated liver metastases [abstract no. 1416]. 39th Annual Meeting of the American Society of Clincal Oncology 2003 May 31-Jun 3; Chicago (IL)
93. Piedbois P, Zelek L, Cherqui D. Chemotherapy of nonoperable colorectal liver metastases. Hepatogastroenterology 2001; 48 (39): 711-4
94. Lygidakis NJ, Sgourakis G, Dedemadi G, et al. Regional chemoimmunotherapy for nonresectable metastatic liver disease of colorectal origin. A prospective randomized study. Hepatogastroenterology 2001; 48 (40): 1085-7
95. Pirovano M, Quinté A, Rivolta R, et al. Intra-arterial infusion of oxaliplatin in colorectal cancer liver metastases: a feasibility study. Tumori 2002; 88: S13
96. Cortesi E, Mancuso A, Giuliani R, et al. A feasibility study of hepatic arterial infusion (HAI) with oxaliplatin in patients with unresectable liver metastases from colorectal cancer (CRC) [abstract no. A40]. Ann Oncol 2001; 12 Suppl. 4: 12
97. Perrone S, Bobbio Pallavicini E, Tacconi F, et al. Oxaliplatin in hepatic arterial infusion (HAI) and systemic chemotherapy with leucovorin plus 5-fluorouracil in metastatic colorectal cancer preliminary data of a multicenter study. Tumori 2002; 88: S13
98. Ducreux M, Ychou M, Boige V, et al. Intraarterial hepatic chemotherapy (IAHC) with oxaliplatin (O) combined to intravenous treatment with 5FU + folinic acid (FA) in hepatic metastases of colorectal cancer (HMCC) [abstract no. 92]. Tumori 2002 Mar; 1 (2 Suppl.): S67-8
99. Boige V, Lacombe S, De Baere T, et al. Hepatic arterial infusion oxaliplatin combined with intravenous 5-FU and folinic acid in non resectable liver metastasis of colorectal cancer: a promising option for failures to systemic chemotherapy [abstract no. 1170]. 39th Annual Meeting American Society of Clinical Oncology 2003 May 31-Jun 3; Chicago (IL)
100. Schalhorn A, Fischer Von Weikersthal L, Queitzsch D, et al. Randomised comparison of irinotecan plus oxaliplatin versus irinotecan plus 5-FU/folinic acid (FA) as first-line treatment in metastatic colorectal cancer (CRC) [abstract no. 1020]. 39th Annual Meeting of the American Society of Clinical Oncology 2003 May 31-Jun 3; Chicago (IL)
101. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 2002 Jan 1; 20 (1): 165-72
102. Yves B, Mousseau M, Gamelin E, et al. Final results of CPT-11 and L-OHP combination versus alternated combination of LVSFU2 + CPT-11/LV5FU2 + L-OHP in 5FU resistant advanced colorectal cancer [abstract no. 978]. Proc Am Soc Clin Oncol 2000 May; 19: 252a
103. Bécouarn Y, Gamelin E, Coudert B, et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001 Nov 15; 19 (22): 4195-201
104. Hartmann JT, Kaechele V, Bokemeyer C, et al. A phase-II-study of dose-dense irinotecan and oxaliplatin as second-line treatment for advanced colorectal cancer [abstract no. 164]. Onkologie 2002 Oct; 25 Suppl. 4: 48
105. Kretzschmar A, Thuss-Patience PC, Pink D, et al. Weekly combination of oxaliplatin (OX) and irinotecan (IRI) in 5-FU resistant colorectal cancer (CRC) [abstract no. 1075]. Eur J Cancer 2001 Oct; 37 Suppl. 6: S291
106. Schüll B, Kornek GV, Schmid K, et al. Second-line treatment of advanced colorectal cancer with a biweekly oxaliplatin plus irinotecan combination regimen. Onkologie 2002 Aug; 25 (4): 358-62
107. Souglakos J, Mavroudis D, Kakolyris S, et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 2002 Jun 1; 20 (11): 2651-7
108. Calvo E, Sureda M, Gassent JM, et al. Bi-weekly triplet combination chemotherapy of oxaliplatin, irinotecan and 5-FU/leucovorin seems to be feasible and safe in metastatic and adjuvant colorectal carcinoma [abstract no. 1265]. 39th Annual Meeting American Society of Clinical Oncology 2003 May 31-Jun 3; Chicago (IL)
109. Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002 Oct 1; 20 (19): 4006-14
110. Stathopoulos GP, Rigatos SK, Stathopoulos JG, et al. Leucovorin, 5-fluorouracil, irinotecan, oxaliplatin combination in pretreated advanced colorectal cancer patients [abstract no. 1213]. 39th Annual Meeting American Society of Clinical Oncology 2003 May 31-Jun 3; Chicago (IL)
111. Calvo E, Cortés J, González-Cao M, et al. Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer: a feasibility pilot study. Oncology 2002; 63 (3): 254-65
112. Calvo E, Cortés J, Rodríguez J, et al. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer 2002 Aug; 2 (2): 104-10
113. Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan (Capiri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC) [abstract no. 1022]. Ann Oncol 2002; 13 Suppl. 5: 71
114. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliptatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003 Apr 1; 21 (7): 1307-12
115. Makatsoris T, Papadimitrou C, Karina M, et al. A phase II study of capecitabine and oxaliplatin as first line treatment for advanced colorectal carcinoma (CRC). A Hellenic Cooperative Oncology Group (He COG) study [abstract no. 1447]. Proc Am Soc Clin Oncol 2003 May; 22: 360
116. Shields AF, Zalupski MM, Marshall JL, et al. A phase II trial of oxaliplatin and capecitabine in patients with advanced colorectal cancer [abstract no. 568]. Proc Am Soc Clin Oncol 2002 May 18; 21 (Pt 1): 143a
117. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002 Apr 1; 20 (7): 1759-66
118. Sastre J, Butts C, Cassidy J, et al. Capecitabine-oxaliplatin combination (XELOX), effective 1st line therapy for patients (pts) with metastatic colorectal cancer (MCRC): survival update of an international phase II trial [abstract no. 288P]. Ann Oncol 2002; 13 Suppl. 5: 80
119. Neri B, Doni L, Fulignati C, et al. Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial. Anticancer Drugs 2002 Aug; 13 (7): 719-24
120. Seitz J-F, Bennouna J, Paillot B, et al. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol 2002 Jul; 13 (7): 1072-9
121. Cascinu S, Graziano F, Ferraú F, et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 2002 May; 13 (5): 716-20
122. Catalano V, Ferraú F, Massacesi C, et al. Raltitrexed (TOM) may replace the de Gramont regimen in combination with oxaliplatin (L-OHP) for the treatment of advanced colorectal cancer [abstract no. 576]. Proc Am Soc Clin Oncol 2001 May 12; 20 (Pt 1): 145a
123. Santini D, Massacesi C, Vincenzi B, et al. Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in advanced colorectal cancer patients: a phase II trial [abstract no. 318]. Ann Oncol 2002; 13 Suppl. 5: 88
124. Scheithauer W, Kornek GV, Ulrich-Pur H, et al. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a phase I-II trial. Cancer 2001 Apr 1; 91: 1264-71
125. Murad A, Scalabrini-Neto AO, Cruz L, et al. Combination of raltitrexed (R) and oxaliplatin (O) as salvage treatment for patients with advanced colorectal cancer (ACRC) refractory to 5-FU based chempotherapy and with hyperexpression of thymidylate synthase (TS) [abstract no, 1372]. Proc Am Soc Clin Oncol 2003; 22: 342
126. Laudani A, Leonardi V, Savio G, et al. Oxaliplatin and raltitrexed in the treatment of advanced colorectal cancer: a phase II study. Ann Oncol 2001; 12 (Suppl. 4): 6
127. Scheithauer W, Kornek GV, Schuell B, et al. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. Ann Oncol 2001 May; 12 (5): 709-14
128. Van Cutsem E, Van Laethem J, Dirix L, et al. Phase II study of raltitrexed in combination with oxaliplatin as second line treatment in refractory advanced colorectal cancer. Eur J Cancer 2001 Oct; 37 Suppl. 6: S273
129. Comella P, Casaretti R, Crucitta E, et al. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. Br J Cancer 2002 Jun 17; 86 (12): 1871-5
130. Casaretti R, De Lucia L, De Vita F, et al. Oxaliplatin (L-OHP) and
131. Cassidy J. Review of oxaliplatin: an active platinum agent in colorectal cancer. Int J Clin Pract 2000; 54 (6): 399-402
132. Cassidy J, Misset J-L. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002 Oct; 29 (5 Suppl. 15): 11-20
133. Jansman FG, Sleijfer DT, de Graaf JC, et al. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf 2001; 24 (5): 353-67
134. Haller DG. Safety of oxaliplatin in the treatment of colorectal cancer. Oncology (Huntingt) 2000 Dec; 14 (12 Suppl. 11): 15-20
135. Sanofi-Synthelabo. Eloxatin (oxaliplatin); summary of product characteristics. Guildford: Sanofi-Synthelabo, 2003
136. Lersch C, Schmelz R, Eckel F, et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2002 May; 2 (1): 54-8
137. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002 Aug 15; 20 (16): 3478-83
138. Gamelin E, Gamelin L, Delva R, et al. Prevention of oxaliplatin peripheral sensory neuropathy by Ca+gluconate/Mg+ chloride infusions: a retrospective study [abstract no. 624]. 39th Annual Meeting of the American Society of Clinical Oncology 2003 May 31-Jun 3; Chicago (IL)
139. Labianca RF, Beretta GD, Pessi MA. Colorectal cancer: disease management considerations. Drugs 2001; 61 (12): 1751-64
140. Giacchetti S. Chronotherapy of colorectal cancer. Chronobiol Int 2002 Jan; 19 (1): 207-19
141. Chau I, Cunningham D. Oxaliplatin for colorectal cancer in the United States: better late than never. J Clin Oncol 2003 Jun 1; 21 (11): 2049-51
142. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000 Sep; 343 (13): 905-14
143. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer. Initial toxicity and response data from a GI Intergroup study [abstract no. 511 plus oral presentation]. Proc Am Soc Clin Oncol 2002 May 1; 21 (Pt 1): 128a
144. Morton RF, Goldberg RM, Sargent DJ, et al. Oxaliplatin (OXAL) or CPT-11 combined with 5FU/leucovorin (LV) in advanced colorectal cancer (CRC): an NCCTG/CALGB study [abstract no. 496]. Proc Am Soc Clin Oncol 2001 May 12; 20 (Pt 1): 125a
145. Sanofi-Synthelabo. Eloxatin (oxaliplatin for injection): summary of product characteristics. Guildford: Sanofi-Synthelabo, 2003
146. Sanofi-Synthelabo Australia Pry Limited. Eloxatin (oxaliplatin for injection): product information. Lane Cove (NSW): Sanofi-Synthelabo Australia Pty Limited. 2002
147. Sanofi-Synthelabo. Eloxatin. Summary of product characteristics. Gentilly: Sanofi-Winthrop, 1999
148. Lévi FA, Zidani R, Vannetzel J-M, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multiinstitutional trial. J Natl Cancer Inst 1994 Nov; 86 (21): 1608-17
149. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000 Mar; 355: 1041-7
150. Rougier P, van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic cancer. Lancet 1998 Oct; 352: 1407-12
151. Cunningham D, Glimelius B. A phase III study of irinotecan (CPT-II) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 1999 Feb; 26 (1 Suppl. 5): 6-12
152. Cassidy J, Cunningham D, Utracka-Hutka B, et al. Oxaliplatin (Oxa)/5-FU/LV in first line metastatic colorectal cancer followed by irinotecan: interim results of the Life Study [abstract no. 1064]. 39th Annual Meeting American Society of Clinical Oncology 2003 May 31-Jun 3; Chicago (IL)